SAN BRUNO, Calif.--(BUSINESS WIRE)--Numerate, Inc., a biotechnology company with a proprietary drug design capability, announced today that it has completed the integration of Pharmix Corporation’s technology platform with technologies developed at Numerate. Founded in March 2007 to rapidly deliver small molecule drug candidates with reduced risk and optimized characteristics, Numerate recently acquired all of the intellectual property of Pharmix, including all rights to Pharmix’s Drug EngineeringTM process and technology, as well as to four therapeutic programs. The terms of the transaction were not disclosed.
